SCHEMBL27168043

SCHEMBL27168043

CC(C)(C)OC(=O)N1CCC(c2ccc(N)cc2)CC1(C)C

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.41
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
NR1H2 P55055 1/20 0.39
HSD11B1 P28845 1/20 0.38
PDE4B Q07343 1/20 0.38
MAPT P10636 2/20 0.37
ALDH1A1 P00352 2/20 0.37
NPC1 O15118 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GPR119 Q8TDV5 3/20 0.37
KDM4E B2RXH2 1/20 0.37
THRB P10828 1/20 0.37
KDM1A O60341 2/20 0.37
HRH3 Q9Y5N1 3/20 0.36
SLC18A3 Q16572 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27167735 1.00 NAMPT (0.41) NAMPTDDB1CRBNNR1H2HSD11B1
SCHEMBL24700142 0.88 NAMPT (0.45) NAMPTHSD11B1MAPTGPR119KDM4E
SCHEMBL27167765 0.87 NAMPT (0.40) NAMPTDDB1CRBNNR1H2HSD11B1
SCHEMBL24793969 0.86 PDE4B (0.39) NAMPTDDB1CRBNNR1H2HSD11B1
SCHEMBL29709707 0.86 PDE4B (0.39) NAMPTDDB1CRBNNR1H2HSD11B1
Formamide SCHEMBL8801927 0.85 NAMPT (0.41) NAMPTHSD11B1MAPTGPR119KDM4E
SCHEMBL270733 0.79 NAMPT (0.60) NAMPTDDB1CRBNNR1H2PDE4B
SCHEMBL17963813 0.78 RORC (0.46) NR1H2HSD11B1
SCHEMBL27168136 0.77 DDB1 (0.58) NAMPTDDB1CRBN
SCHEMBL503247 0.77 PDE4B (0.58) NAMPTDDB1CRBNNR1H2PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287076-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE C4 THERAPEUTICS, INC. 2024-08-29 US disclosed
EP-4333899-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE Biogen MA Inc. (US) 2024-03-13 EP disclosed
CN-117580592-A Compounds for targeting bruton's tyrosine kinase degradation 渤健马萨诸塞州股份有限公司 2024-02-20 CN disclosed
WO-2022235945-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE BIOGEN MA INC. (US) 2022-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287076-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE BTK, SYK, LYN NAMPT 3989/4885DDB1 729/4885CRBN 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.